Abstract
Purpose :
To evaluate the efficacy of an anterior chamber intracameral dexamethasone drug-delivery suspension (Dexycu; EyePoint Pharmaceuticals, Watertown, MA) that provides medication for up to 21 days with a single application in treating postoperative inflammation in patients undergoing vitreoretinal surgery compared to daily post-operative treatment with topical corticosteroids for up to 1 month.
Methods :
Retrospective case-matched comparison of patients undergoing initial vitreoretinal surgery by a single surgeon. Patients had a preoperative best-corrected visual acuity of 20/20 to light perception and a variety of vitreoretinal pathologies. 27 eyes of 27 patients received intracameral dexamethasone at the time of surgery and were compared to 27 eyes of 27 patients who received daily post-operative corticosteroid eye drops over 4 weeks. Primary outcome was anterior chamber cell (ACC) clearing (ACC score of 0) in the study eye at postoperative day (POD) 7. Ocular adverse events were assessed through POD 90. A chi-square test was used for statistical analysis.
Results :
Anterior chamber cell clearing at POD 7 was achieved in 38% of eyes in the topical steroid-treated group and in 67% in the intracameral dexamethasone treatment group, respectively (P =0.029). No serious ocular adverse events were noted up to POD 90 in either group.
Conclusions :
The intracameral dexamethasone drug-delivery suspension placed in the anterior chamber after vitreoretinal surgery was more effective than topical corticosteroids in treating inflammation occurring 1 week following vitreoretinal surgery and thus may be an alternative to daily corticosteroid drop installation in this patient population.
This is a 2020 ARVO Annual Meeting abstract.